Sugi Predict

Sugi Predict / Targets / BAK1

BAK1

Bcl-2 homologous antagonist/killer · Q16611 · BAK1 on Sugi Atlas →

33,039 patent compounds predicted against BAK1, 15,303 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL300853 SCHEMBL300853 0.97 6/20
Gingkolic Acid Gingkolic Acid (SCHEMBL163525) 0.95 6/20
SCHEMBL154719 SCHEMBL154719 0.85 6/20
Anacardic Acid Anacardic Acid (SCHEMBL154720) 0.73 6/20
SCHEMBL23277 SCHEMBL23277 0.72 6/20
SCHEMBL300614 SCHEMBL300614 0.72 6/20
SCHEMBL301487 SCHEMBL301487 0.72 6/20
SCHEMBL485756 SCHEMBL485756 0.72 6/20
SCHEMBL244743 SCHEMBL244743 0.70 6/20
SCHEMBL376922 SCHEMBL376922 0.64 6/20
SCHEMBL409185 SCHEMBL409185 0.62 6/20
SCHEMBL211983 SCHEMBL211983 0.58 6/20
SCHEMBL105964 SCHEMBL105964 0.61 5/20
SCHEMBL315846 SCHEMBL315846 0.61 5/20
Acrylic Acid Acrylic Acid (SCHEMBL111782) 0.60 5/20
Methacrylic Acid Methacrylic Acid (SCHEMBL112437) 0.60 5/20
SCHEMBL97903 SCHEMBL97903 0.59 5/20
SCHEMBL574314 SCHEMBL574314 0.59 5/20
SCHEMBL574395 SCHEMBL574395 0.59 5/20
SCHEMBL574605 SCHEMBL574605 0.59 5/20

Clinical trials — most relevant to BAK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma PHASE1/PHASE2NOT_YET_RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL PHASE2ACTIVE_NOT_RECRUITING
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors PHASE1UNKNOWN
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma PHASE1COMPLETED
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS PHASE1RECRUITING
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE1SUSPENDED
Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2 nanUNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia nanRECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML nanRECRUITING
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BAK1 binder may also engage these)

ProteinNameSimilarity
O08734 — 0.992 O08734 →
O02703 — 0.985 O02703 →
BCL2L1 Bcl-2-like protein 1 0.985 landscape →
O77737 — 0.984 O77737 →
Q6R755 — 0.982 Q6R755 →
Q07816 — 0.982 Q07816 →
Q9JJV8 — 0.982 Q9JJV8 →
Q64373 — 0.982 Q64373 →
P53563 — 0.981 P53563 →
Q4JHS0 — 0.980 Q4JHS0 →
Q63690 — 0.979 Q63690 →
BAX Apoptosis regulator BAX 0.979 landscape →
BID BH3-interacting domain death agonist 0.976 landscape →
Q91828 — 0.976 Q91828 →
Q9JLT6 — 0.976 Q9JLT6 →
P49950 — 0.975 P49950 →
Q00709 — 0.975 Q00709 →
P70444 — 0.975 P70444 →
Q1RMX3 — 0.975 Q1RMX3 →
BCL2 Apoptosis regulator Bcl-2 0.974 landscape →
A1L1L2 — 0.974 A1L1L2 →
Q6NUQ4 — 0.973 Q6NUQ4 →
O02718 — 0.973 O02718 →
Q07813 — 0.973 Q07813 →
Q91WR3 — 0.972 Q91WR3 →
Q8BK08 — 0.972 Q8BK08 →
P10417 — 0.971 P10417 →
BCL2L2 Bcl-2-like protein 2 0.971 landscape →
A4FV45 — 0.971 A4FV45 →
Q8BK03 — 0.971 Q8BK03 →